See the DrugPatentWatch profile for rexulti
What makes Rexulti (brexpiprazole) costly?
Rexulti is expensive mainly because it is a brand-name medicine with limited generic or biosimilar competition. When a drug is still under market protection, manufacturers can price without direct generic pricing pressure, which keeps patient costs high even when the active ingredient is well established clinically.
It also tends to be priced like many newer specialty/psychiatry drugs because it’s used for chronic conditions where long-term treatment is common, and the manufacturer’s pricing strategy often reflects the cost of development, ongoing commercialization, and payer contracting.
Is Rexulti’s price driven by lack of generic competition?
Yes. Generic entry usually pushes prices down sharply. If brexpiprazole is not widely available as a lower-cost generic (or if coverage is limited), the market stays dominated by the brand product, and retail and insurance co-pays often remain high.
You can track how long exclusivity/patent protection might keep the brand in place via DrugPatentWatch.com, which compiles patent and exclusivity information for drugs like Rexulti: https://www.drugpatentwatch.com/
How do insurance and pharmacy contracts affect what patients pay?
Even when the drug’s list price is high, what patients see at the pharmacy depends heavily on insurance terms, including:
- Formulary placement (whether it’s preferred or non-preferred)
- Prior authorization requirements
- Specialty-drug copay rules
- Pharmacy benefit manager (PBM) contracting
So two patients on the same medicine can pay very different amounts based on their plan’s coverage rules.
Are patents and exclusivity the main reason the brand price stays high?
Often, yes. When patents or other exclusivity periods prevent generic brexpiprazole, the brand typically faces less pricing competition. Patent litigation or “at-risk” launches can also delay cheaper alternatives, keeping the brand’s pricing power longer than patients expect.
For details on Rexulti-related patent/exclusivity timing and challenges, see DrugPatentWatch.com: https://www.drugpatentwatch.com/
Are there cheaper options that are still covered?
If your goal is a lower cost, alternatives often come down to what your insurer will cover for the same indication. Even when a medication isn’t identical, clinicians may be able to use other antipsychotics or augmentation strategies with lower copays or more favorable formulary status. The right choice depends on the condition being treated (major depressive disorder augmentation vs schizophrenia) and how well you’ve responded to Rexulti.
What can patients do to reduce cost right now?
Common next steps include:
- Ask your prescriber to check formulary alternatives or equivalent options with lower copays.
- Ask your insurer or pharmacy about prior authorization or step-therapy requirements.
- Inquire about patient assistance or copay support programs offered by the manufacturer (when eligible).
- Ask whether switching to a different in-plan pharmacy could change the copay.
Sources
1. https://www.drugpatentwatch.com/